dfda compounded glp-1 receptor agonists - Semaglutide & Tirzepatide FDA Updates on Compounded GLP-1
Description
Learn about the Zepbound blindness lawsuit, including NAION and other eye side effects, and read about a study linking GLP-1 RAs to severe vision problems.
The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.
Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption
In the quest for optimal health, the spotlight is increasingly turning to metabolic balance
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)
Dosing in kidney and liver disease is also covered, along with drug interactions.
